Table 1.
Baseline demographic and clinical characteristics.
| Characteristic | Cohort 1 (n = 44) | Cohort 2 (n = 19) | Cohort 3 (n = 20) |
|---|---|---|---|
| Age, years | |||
| Median (range) | 57.6 (44.3–73.0) | 60.2 (34.7–64.9) | 60.0 (31.6–73.4) |
| <65, n (%) | 35 (79.5) | 19 (100.0) | 16 (80.0) |
| ≥65, n (%) | 9 (20.5) | 0 (0.0) | 4 (20.0) |
| Sex, n (%) | |||
| Male | 105 (77.8) | 6 (31.6) | 16 (80.0) |
| Female | 30 (22.2) | 13 (68.4) | 4 (20.0) |
| ECOG performance status score, n (%) | |||
| 0 | 28 (63.6) | 5 (26.3) | 1 (5.0) |
| 1 | 16 (36.4) | 14 (73.7) | 19 (95.0) |
| Smoking status, n (%) | |||
| Current or former | 24 (54.5) | 4 (21.1) | 15 (75.0) |
| Never | 20 (45.5) | 15 (78.9) | 5 (25.0) |
| PD-L1 tumor proportion score, n (%) | |||
| <1% | 20 (45.5) | 10 (52.6) | 6 (30.0) |
| 1–49% | 16 (36.4) | 6 (31.6) | 8 (40.0) |
| ≥50% | 6 (13.6) | 3 (15.8) | 4 (20.0) |
| Unknown | 2 (4.5) | 0 (0.0) | 2 (10.0) |
| Disease stage, n (%) | |||
| III | 4 (9.1) | 0 (0.0) | 3 (15.0) |
| IV | 40 (90.9) | 19 (100.0) | 17 (85.0) |
| Brain metastases, n (%) | 11 (25.0) | 7 (36.8) | 1 (5.0) |
| Number of distant metastases (excluding lungs), n (%) | |||
| <3 | 32 (72.7) | 9 (47.4) | 15 (75.0) |
| ≥3 | 12 (27.3) | 10 (52.6) | 5 (25.0) |
| Histologic features, n (%) | |||
| Squamous | 18 (40.9) | 0 (0.0) | 7 (35.0) |
| Non-squamous | 26 (59.1) | 19 (100.0) | 13 (65.0) |
| EGFR mutation status (cohort 2), n (%) | |||
| 19del and T790M+ | 0 | 8 (42.1) | 0 |
| 19del and T790M- | 0 | 5 (26.3) | 0 |
| L858R and T790M+ | 0 | 2 (10.5) | 0 |
| L858R and T790M- | 0 | 3 (15.8) | 0 |
| G719X and T790M- | 0 | 1 (5.3) | 0 |
| Generation of previous EGFR-TKIs (cohort 2), n (%) | |||
| First or second | 0 | 5 (26.3) | 0 |
| First or second, followed by third | 0 | 14 (73.7) | 0 |
| Third as first-line | 0 | 0 | 0 |
| Using bevacizumab (cohort 3), n (%) | |||
| Yes | 0 | 0 | 4 (20.0) |
| No | 0 | 0 | 16 (80.0) |
| Lines of prior cancer therapy (cohorts 2 and 3), n (%) | |||
| 1 | 0 | 5 (26.3) | 14 (70.0) |
| ≥2 | 0 | 14 (73.7) | 6 (30.0) |
| The best curative effect of previous treatments (cohorts 2 and 3), n (%) | |||
| CR/PR | NA | 4 (21.1) | 8 (40.0) |
| SD | NA | 0 (0.0) | 7 (35.0) |
| PD | NA | 1 (5.3) | 0 (0.0) |
| Unknown | NA | 13 (68.4) | 5 (25.0) |
| Missing | NA | 1 (5.3) | 0 (0.0) |
n, number; ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NA, not applicable.